• AbbVie receives EC grant to market HCV treatment Maviret pharmaceutical-technology
    August 02, 2017
    The European Commission (EC) has granted marketing authorisation for AbbVie’s Maviret (glecaprevir / pibrentasvir) to treat adult patients with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).
PharmaSources Customer Service